Rigel Pharmaceuticals Reports Preliminary Efficacy of R289 in Lower-Risk MDS Patients
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 11 hour ago0mins
- Preliminary Efficacy Observed: In lower-risk MDS patients receiving doses of ≥500 mg QD, 33% of transfusion-dependent patients achieved red blood cell transfusion independence (RBC-TI), indicating R289's potential as a new treatment option in this challenging area.
- Patient Demographics: The median age of participants was 75, with 76% having previously received treatments like luspatercept, highlighting the drug's applicability in a difficult-to-treat population and its potential to improve patient quality of life.
- Good Tolerability: R289 was generally well tolerated across all dose groups, with a median treatment duration of 5.5 months, suggesting its safety in heavily pre-treated patients and providing confidence for future clinical trials.
- Future Research Outlook: Rigel anticipates selecting the recommended Phase 2 dose in the second half of 2026, aiming to further validate R289's efficacy and potentially offer new hope for lower-risk MDS patients.
RIGL.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on RIGL
Wall Street analysts forecast RIGL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RIGL is 45.67 USD with a low forecast of 38.00 USD and a high forecast of 57.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 47.380
Low
38.00
Averages
45.67
High
57.00
Current: 47.380
Low
38.00
Averages
45.67
High
57.00
Cantor Fitzgerald
Neutral
maintain
$32 -> $38
2025-11-05
Reason
Cantor Fitzgerald
Price Target
$32 -> $38
2025-11-05
maintain
Neutral
Reason
Cantor Fitzgerald raised the firm's price target on Rigel Pharmaceuticals to $38 from $32 and keeps a Neutral rating on the shares. The strong quarter on TAVALISSE $44.7M proved that the strong uptick we saw in Q3 wasn't a one-time fluke, the analyst tells investors in a research note. The firm thinks the pipeline opportunity deserves "equal attention" in light of the trends from TAVALISSE in 2025.
Jefferies
Hold
to
Buy
upgrade
$42
2025-11-05
Reason
Jefferies
Price Target
$42
2025-11-05
upgrade
Hold
to
Buy
Reason
Jefferies upgraded Rigel Pharmaceuticals to Buy from Hold with a $42 price target.
Jefferies
Hold -> Buy
upgrade
$23 -> $42
2025-11-05
Reason
Jefferies
Price Target
$23 -> $42
2025-11-05
upgrade
Hold -> Buy
Reason
As previously reported, Jefferies upgraded Rigel Pharmaceuticals to Buy from Hold with a price target of $42, up from $23, after Q3 product sales beat Street expectations and the company raised total 2025 net product sales guidance to $225M-$230M from $210M-$220M. The firm cites strong commercial execution, positive cash flow and room for potential business development for its upgrade.
Citigroup
Yigal Nochomovitz
Strong Buy
Maintains
$49 → $55
2025-03-06
Reason
Citigroup
Yigal Nochomovitz
Price Target
$49 → $55
2025-03-06
Maintains
Strong Buy
Reason
See All Ratings
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What does Rigel Pharmaceuticals' Momentum Style Score of A signify?
How does momentum investing relate to Rigel Pharmaceuticals' recent performance?
Will Rigel Pharmaceuticals' stock continue to outperform the S&P 500?
How might R289's Phase 2 trials impact Rigel's market position in 2026?